Oncology Institute (TOIIW) Cash & Equivalents (2019 - 2026)

Oncology Institute (TOIIW) has reported Cash & Equivalents for 8 consecutive years, with $30.3 million the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $30.3 million, down 23.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.3 million (down 23.8% YoY), and the FY2025 annual result was $33.6 million, down 32.42% from the prior year.
• Cash & Equivalents was $30.3 million for Q1 2026 at Oncology Institute, down from $33.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $95.5 million in Q1 2022 and troughed at $14.0 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $39.5 million, with a median of $33.6 million recorded in 2025.
• The widest YoY moves for Cash & Equivalents: up 432.65% in 2022, down 87.84% in 2022.
• Over 5 years, Cash & Equivalents stood at $14.0 million in 2022, then surged by 139.03% to $33.5 million in 2023, then jumped by 48.32% to $49.7 million in 2024, then sank by 32.42% to $33.6 million in 2025, then retreated by 9.79% to $30.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $30.3 million in Q1 2026, $33.6 million in Q4 2025, and $27.7 million in Q3 2025.